Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.
| Website | http://www.boldentherapeutics.com |
| Employees | 2 (1 on RocketReach) |
| Founded | 2019 |
| Address | 225 Dyer St, Providence, Rhode Island 02903, US |
| Phone | +1 617-864-0880 |
| Industry | Biotechnology Research |
| Keywords | Central Nervous System, Biotechnology, Neurodegenerative Diseases, Biopharma, Therapeutics, First In Class, Drug Development, Alzheimers Treatment, Pharmaceutical Research, Innovative Therapies, New Drug Discovery, Drug Discovery, Stroke Treatment, Clinical Trials, Medicine, Treatment |
| Competitors | CureVac, Moderna Therapeutics, Arcturus Therapeutics, RaNA Therapeutics, GSK, Novavax, Sanofi, Pfizer, Merck & Co., Inc., Regeneron +39 more (view full list) |
Looking for a particular Bolden Therapeutics employee's phone or email?
Johnny Page is the Co-Founder and CEO of Bolden Therapeutics.
1 people are employed at Bolden Therapeutics.
Bolden Therapeutics is based in Providence, Rhode Island.